CPT-11 (Irinotecan) — Competitive Intelligence Brief

CPT-11 (Irinotecan) (CPT-11 (Irinotecan)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topoisomerase I inhibitor. Area: Oncology.

phase 3 Topoisomerase I inhibitor Topoisomerase I Oncology Small molecule

Target snapshot

CPT-11 (Irinotecan) (CPT-11 (Irinotecan)) — Epidemiological and Clinical Research Information Network. CPT-11 (irinotecan) is a topoisomerase I inhibitor that prevents DNA unwinding and repair, leading to DNA damage and cancer cell death.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CPT-11 (Irinotecan) TARGET	CPT-11 (Irinotecan)	Epidemiological and Clinical Research Information Network	phase 3	Topoisomerase I inhibitor	Topoisomerase I
Camptosar	irinotecan	Pfizer	marketed	Topoisomerase Inhibitor	topoisomerase I	1996-01-01
Idamycin Pfs	IDARUBICIN HYDROCHLORIDE		marketed	Anthracycline Topoisomerase Inhibitor	DNA, topoisomerase II	1990-01-01
Idamycin Pfs	Idarubicin Hydrochloride	Pfizer Inc.	marketed	Anthracycline topoisomerase inhibitor	DNA, Topoisomerase II	1990-01-01
Idamycin Pfs	Idarubicin Hydrochloride	Pfizer Inc.	marketed	Anthracycline topoisomerase inhibitor	DNA, Topoisomerase II	1990-01-01
Cipro	ciprofloxacin	Bayer AG	marketed	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Amekrin	AMSACRINE		marketed	amsacrine	DNA topoisomerase 2-beta, Solute carrier family 22 member 1, DNA topoisomerase II	1987-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2029-04-21 — Cipro · 11369566 · Formulation · US
• 2029-04-21 — Cipro · 9603796 · Compound · US
• 2029-04-21 — Cipro · 9205048 · Method of Use · US
• 2029-12-11 — Cipro · 9233068 · Formulation · US
• 2030-04-27 — Cipro · 8318817 · Method of Use · US
• 2035-07-01 — Cipro · 9220796 · Formulation · US
• 2037-11-12 — Cipro · 11040004 · Method of Use · US
• 2038-11-27 — Cipro · 11246863 · Formulation · US

Sponsor landscape (Topoisomerase I inhibitor class)

1. Accelerated Community Oncology Research Network · 1 drug in this class
2. Amgen · 1 drug in this class
3. Cancer Advances Inc. · 1 drug in this class
4. Chinese Academy of Medical Sciences · 1 drug in this class
5. Daiichi Sankyo Co., Ltd. · 1 drug in this class
6. Epidemiological and Clinical Research Information Network · 1 drug in this class
7. GlaxoSmithKline · 1 drug in this class
8. Seoul National University Hospital · 1 drug in this class
9. St. Jude Children's Research Hospital · 1 drug in this class
10. Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class